The American Gastroenterological Association's 2022 clinical practice guideline on obesity pharmacotherapy, published in Gastroenterology, states: "We suggest using semaglutide 2.4 mg subcutaneous weekly for adults with obesity or overweight with weight-related comorbidities (conditional recommendation, moderate-certainty evidence)." This guideline also notes that pharmacotherapy should accompany, not replace, lifestyle intervention
The main drawback of CPT1A blockage is the undesirable impact on non-tumor cells given the extensive tissue distribution of CPT1A
Schooling CM, Lopez P, Yang Z, Zhao JV, Au Yeung SL, Huang JV
Superiority for HbA 1c had to be established at higher doses before testing hypotheses at lower doses (ESM Fig
Convenient and easy to use Semaglutide GLP-1 should be injected once a week and is easy to use
The FDA has published safety concerns about compounded GLP-1 products, including dosing errors and adverse events